Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

True Health

Explore full profile

Innovative medical robotic surgery and digital transformation in healthcare in medical practice, with a focus on financial management and expert recognition, and further development through…

Zhuhai, ChinaFounded 2018Health Tech & Medtech
Valuation $50–100M Last recorded · 2023
Revenue $1–10M Latest reported FY
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for True Health and the history behind them.

About True Health

True Health (Beijing) Medical Technology Co., Ltd., operating as True Health, is a medical technology firm established in March 2018. The company was founded by individuals with extensive experience in the medical, surgical robotics, and information technology sectors. The founder and chairwoman, Zhang Haoren, previously worked at the Pharmaceutical Administration Bureau in Macau, managing narcotic and psychotropic drugs, before venturing into drug and medical device research and development in mainland China in 2000. The core team is primarily composed of individuals with master's and doctoral degrees from Beihang University.

Read full description

True Health focuses on the precise diagnosis and minimally invasive treatment of tumors, particularly lung cancer. The company operates in the medical robotics and artificial intelligence market, serving hospitals and medical professionals. Its business model revolves around the research, development, production, and sale of surgical robots. A significant milestone was achieved in May 2022, when its first-generation puncture surgical robot, Zhenyida®, received a Class III medical device registration certificate from the National Medical Products Administration (NMPA), which recognized it as a domestic first. By January 2024, the company had secured two Class III and three Class II medical device registration certificates. In a notable achievement, True Health won first prize and a 50 million yuan award in the growth group of the 3rd Hengqin International Science and Technology Innovation Competition in January 2024.

The company's flagship product is the "Zhenyida®" soft tissue puncture surgical robot, a system designed to assist physicians in performing safe and precise lesion punctures. This technology integrates intelligent lesion identification through automatic image analysis, puncture path planning, surgical environment perception, and robotic arm-assisted puncture. Key features of the system include an image analysis and puncture planning system that automatically identifies lesions and reconstructs anatomical structures in 3D, an optical navigation system for sub-millimeter positioning accuracy, a breathing tracking system to monitor patient respiratory movement, and a multi-axis robotic arm for stable and precise execution of the puncture plan. The robot aims to enhance the accuracy and efficiency of puncture procedures, reduce complications, and make advanced diagnostic and therapeutic methods more widely accessible by lowering the dependency on a physician's experience level. The system has various clinical applications, including tissue biopsy, tumor ablation, preoperative lung cancer localization, and radioactive seed implantation.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
Zhuhai, China
Open positions
None listed
Dealroom signal
19.7/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Precision Medicine, Hard Tech
Business model
Manufacturing
Client focus
b2b
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit Jun 2026 $54M — Undisclosed ↗
SERIES B✓Equity / VC Nov 2023 $14M $55M Undisclosed ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

True Health website traffic

Latest recorded traffic for True Health is 330 monthly website visits, up 32% over the last three months.

Latest monthly visits330 3-month web change+32%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Zhuhai HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about True Health on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See True Health’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.